{"title":"索拉非尼治疗肝细胞癌。","authors":"Debra H Josephs, Paul J Ross","doi":"10.12968/hmed.2010.71.8.77669","DOIUrl":null,"url":null,"abstract":"<p><p>Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.</p>","PeriodicalId":520576,"journal":{"name":"British journal of hospital medicine (London, England : 2005)","volume":" ","pages":"451-6"},"PeriodicalIF":1.8000,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.12968/hmed.2010.71.8.77669","citationCount":"7","resultStr":"{\"title\":\"Sorafenib in hepatocellular carcinoma.\",\"authors\":\"Debra H Josephs, Paul J Ross\",\"doi\":\"10.12968/hmed.2010.71.8.77669\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.</p>\",\"PeriodicalId\":520576,\"journal\":{\"name\":\"British journal of hospital medicine (London, England : 2005)\",\"volume\":\" \",\"pages\":\"451-6\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2010-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.12968/hmed.2010.71.8.77669\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of hospital medicine (London, England : 2005)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2010.71.8.77669\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of hospital medicine (London, England : 2005)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/hmed.2010.71.8.77669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
